Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

Affiliations

¹ General Medicine 2, Center for the Study of Myelofibrosis, Policlinico S. Matteo Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy; and.
² Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.

Comment

Giovanni Barosi et al. Blood Adv. 2022.

. 2022 Apr 12;6(7):2331-2333.

doi: 10.1182/bloodadvances.2022007230.

¹ General Medicine 2, Center for the Study of Myelofibrosis, Policlinico S. Matteo Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy; and.
² Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.

No abstract available

Comment on

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larràn A, Andreasson B, Vannucchi AM, Barbui T. Guglielmelli P, et al. Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. Blood Adv. 2022. PMID: 34753179 Free PMC article. No abstract available.

1. Guglielmelli P, Ghirardi A, Carobbio A, et al. . Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2022;6(2):373-375. - PMC - PubMed
1. Verstovsek S, Mesa RA, Gotlib J, et al. . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. - PMC - PubMed
1. Verstovsek S, Mesa RA, Gotlib J, et al. . Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871. - PMC - PubMed
1. Harrison C, Kiladjian JJ, Al-Ali HK, et al. . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798. - PubMed
1. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. ; COMFORT-II investigators . Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [published correction appears in Blood. 2016;128(25):3013]. Blood. 2013;122(25):4047-4053. - PubMed